secwatch.observer — SEC 8-K summary
======================================

Issuer:     Werewolf Therapeutics, Inc. (HOWL)
CIK:        0001785530
Form:       8-K
Filed at:   2021-10-28T23:59:59+00:00
Accession:  0001785530-21-000043
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Werewolf Therapeutics appoints Meeta Chatterjee, Ph.D. to Board
---------------------------------------------------------------

- Dr. Chatterjee appointed as Class II director, term until 2023 annual meeting.
- She is Senior VP of Global Business Development at Legend Biotech; previously at Merck.
- Receives $35,000 annual cash, $4,000 committee retainer, plus option grant of 23,200 shares at $15.97.
- Appointed to Nominating and Corporate Governance Committee.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1785530/000178553021000043/0001785530-21-000043-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1785530/000178553021000043/howl-20211028.htm
  HTML page:      https://secwatch.observer/filing/0001785530-21-000043

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer